#MSVirtual2020

#MSVirtual2020 – Masitinib Delays Disability Progression in PPMS, Non-active SPMS

AB Scienceā€™s lead candidate masitinibĀ safely and effectively delays disability progression in people withĀ primary progressive multiple sclerosisĀ (PPMS) and non-activeĀ secondary progressive MSĀ (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to reduce…

#MSVirtual2020 – Pediatric MS Patients May Do Best on Intravenous DMTs, Study Finds

Most children and adolescents with pediatric-onset multiple sclerosis (POMS), especially those treated intravenously with a disease-modifying therapyĀ (DMT), achieve no evidence of disease activity within two years of diagnosis, according to a real-life study from the U.S. Patients whose DMTs are infused into a vein (intravenous treatment) areĀ more likely…

#MSVirtual2020 ā€“ Remyelination Mainly Conducted by Pre-existing Myelin-producing Cells, Study Finds

Remyelination ā€” or the restoration of lost myelin, the protective sheath surrounding nerve cell fibers ā€” in multiple sclerosis (MS) depends mainly on pre-existing oligodendrocytes (myelin-producing cells), rather than on newly-generated oligodendrocytes, according to a recent study. The data also showed that perineuronal, or satellite,…

#MSVirtual2020 – Early Intensive DMT Use in RRMS Appears More Effective Than Escalation

Early use of high efficacy disease-modifying therapies (DMTs) is more effective than the traditional approach ā€” that of an escalating treatment regimen ā€” at delaying disability progression in people with relapsing-remitting multiple sclerosisĀ (RRMS), a real-life study from Italy reports. People later moving to more aggressive treatment also appeared…

#MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show

Janssen Pharmaceuticalsā€™ investigational oral therapy ponesimod is superior to Sanofiā€™s Aubagio (teriflunomide) in delaying disability progression in adults with relapsing multiple sclerosis (MS), according to exploratory analyses of OPTIMUM clinical trial data. These and other findings from Janssenā€™s MS research program, including on the health…

#MSVirtual2020 ā€” No Evidence of Disease Activity Seen in Most RRMS Patients After Switching to Ocrevus, Data Show

Switching to Genentechā€™s OcrevusĀ (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of no evidence of disease activity in people withĀ relapsing-remitting multiple sclerosisĀ (RRMS), according to data from a Phase 3b clinical trial. That finding, as well as data about patients’ adherence and…

#MSVirtual2020 ā€“ Meeting Focus Is on Advances in MS Research, Diagnostics, and Technology

The upcoming MSVirtual2020 meeting, the largest international conference dedicated to multiple sclerosisĀ (MS) research, will focus on advances and breakthroughs made in MS causes and risk factors, diagnostic tools, treatment response biomarkers, technology, and therapies and interventions. The 8th joint meeting of the Americas Committee for Treatment and…

#MSVirtual2020 ā€“ Zeposia Still Prevents Relapses in Relapsing MS Patients After 3 Years, Trial Data Show

Zeposia (ozanimod) oral capsules continue to safely and effectively prevent relapses and disability progression in people with relapsing forms of multiple sclerosis (MS), according to three-year data from a Phase 3 extension clinical trial. ā€œGaining insight into long-term therapeutic outcomes can enable clinicians to identify the most appropriate…